Sign In
Buy GCTK
$5.20
+0.0200 (+0.386%)
At Close: Nov 17, 2025
Glucotrack Reports Third Quarter 2025 Financial Results and Provides Update on Recent Corporate Highlights
04:05pm, Thursday, 13'th Nov 2025
Company to submit Investigational Device Exemption (IDE) to FDA for novel CBGM technology in Spring 2026 Expanded clinical advisory team with appointment of pain management and medical technology expe
Glucotrack, Inc. Encourages Shareholders to Vote
04:05pm, Monday, 03'rd Nov 2025
The Special Meeting of Shareholders reconvenes on November 7, 2025 Shareholders vote on Equity Purchase Agreement with Sixth Borough Capital Fund RUTHERFORD, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) --
Glucotrack Appoints Neuromodulation and Painful Diabetic Neuropathy Expert, Usman Latif, MD, MBA, to Clinical Advisory Team
04:05pm, Wednesday, 29'th Oct 2025
RUTHERFORD, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc.(“Glucotrack”, or the “Company”) (Nasdaq: GCTK), a medical device company focused on the design, development, and commercial
Glucotrack, Inc. Reminds Shareholders to Vote
08:00am, Tuesday, 28'th Oct 2025
The Special Meeting of Shareholders held on October 31, 2025 Shareholders vote on Equity Purchase Agreement with Sixth Borough Capital Fund RUTHERFORD, N.J., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Glucot
Glucotrack to Participate in the Q3 Virtual Investor Summit
08:00am, Thursday, 11'th Sep 2025
RUTHERFORD, N.J., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and comme
Glucotrack Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
04:05pm, Thursday, 14'th Aug 2025
On track to implant first patients in long-term, multicenter feasibility study of the fully implantable continuous blood glucose monitor (CBGM) system in Australia in Q3 2025
Glucotrack Expands Clinical Advisory Team Appointing David S. Hirsh, MD as Medical Director, Cardiology
08:30am, Wednesday, 06'th Aug 2025
Experienced cardiac electrophysiologist joins Glucotrack's growing clinical advisory team as the Company advances its long-term CBGM through critical clinical milestones Experienced cardiac electrophy
Glucotrack to Exhibit at 2025 Association of Diabetes Care and Education Specialists Annual Meeting
08:30am, Thursday, 31'st Jul 2025
Company to present endocrinologist perspectives on implantable CBGM technology as it advances toward US pilot study Company to present endocrinologist perspectives on implantable CBGM technology as it
Glucotrack Announces Repurchase of Series A Warrants
08:30am, Tuesday, 08'th Jul 2025
RUTHERFORD, N.J., July 08, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people
Why Is This Nano-Cap Glucotrack Stock Trading Higher On Wednesday?
10:40am, Wednesday, 25'th Jun 2025
Glucotrack Inc. GCTK stock traded higher on Wednesday, with a session volume of 15.91 million compared to the average of 81.7K, according to data from Benzinga Pro.
RUTHERFORD, N.J. and STOCKHOLM, June 25, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical device company focused on the design, development, and commercialization of novel technolog
Glucotrack Announces Reverse Stock Split Shareholder Approved Action Meets NASDAQ Panel Hearing Listing Requirements
09:05am, Thursday, 12'th Jun 2025
1-for-60 reverse stock split to become effective as of the opening of trading on June 16, 2025 Rutherford, NJ, June 12, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or th
Glucotrack to Showcase Long-Term Continuous Blood Glucose Monitor at American Diabetes Association's 85th Scientific Sessions
08:30am, Wednesday, 04'th Jun 2025
Glucotrack to present on next-generation continuous blood glucose monitoring technology in Innovation Hub Poster presentation to highlight insights on safety and performance data from direct blood glu
Glucotrack Strengthens Board of Directors with Election of Victoria E. Carr-Brendel, PhD
08:30am, Wednesday, 28'th May 2025
Experienced medical device executive with deep expertise in implantable technologies joins Glucotrack as Company advances development of long-term implantable blood glucose monitoring technology Exper
Glucotrack Establishes Patient Advisory Board to Inform Diabetes Technology Development
08:30am, Tuesday, 20'th May 2025
Patients get a seat at the table in development of long-term implantable continuous blood glucose monitoring technology Patients get a seat at the table in development of long-term implantable continu
